Abnormalities of age-related T cell senescence in Parkinson’s disease

Abstract

BackgroundA wealth of evidence implicates both central and peripheral immune changes as contributing to the pathogenesis of Parkinson’s disease (PD). It is critical to better understand this aspect of PD given that it is a tractable target for disease-modifying therapy. Age-related changes are known to occur in the immune system (immunosenescence) and might be of particular relevance in PD given that its prevalence rises with increasing age. We therefore sought to investigate this with respect to T cell replicative senescence, a key immune component of human ageing.MethodsPeripheral blood mononuclear cells were extracted from blood samples from 41 patients with mild PD (Hoehn and Yahr stages 1–2, mean (SD) disease duration 4.3 (1.2) years) and 41 age- and gender-matched controls. Immunophenotyping was performed with flow cytometry using markers of T lymphocyte activation and senescence (CD3, CD4, CD8, HLA-DR, CD38, CD28, CCR7, CD45RA, CD57, CD31). Cytomegalovirus (CMV) serology was measured given its proposed relevance in driving T cell senescence.ResultsMarkers of replicative senescence in the CD8+ population were strikingly reduced in PD cases versus controls (reduced CD57 expression (p = 0.005), reduced percentage of ‘late differentiated’ CD57loCD28hi cells (p = 0.007) and ‘TEMRA’ cells (p = 0.042)), whilst expression of activation markers (CD28) was increased (p = 0.005). This was not driven by differences in CMV seropositivity. No significant changes were observed in the CD4 population.ConclusionsThis study demonstrates for the first time that the peripheral immune profile in PD is distinctly atypical for an older population, with a lack of the CD8+ T cell replicative senescence which characterises normal ageing. This suggests that ‘abnormal’ immune ageing may contribute to the development of PD, and markers of T cell senescence warrant further investigation as potential biomarkers in this condition.

Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson’s Disease: The ICICLE-PD Study

“…These observations add to existing evidence suggesting that the association of senescence of blood cells with neurodegenerative diseases might not be as simple as originally thought. In particular, our own previous immuno-phenotyping studies showed a reduction of 'late senescent' CD8+ T cells (identified as CD28 lo CD57 hi ) in PD cases versus controls [62]. Furthermore, in AD patients monocytic p21 protein levels were decreased compared to control individuals [59].…”

The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease

“…Exclusion criteria were: other neurodegenerative disorders, chronic inflammatory or autoimmune disorders, current clinically significant infection or use of anti-inflammatory/immunomodulatory medications, surgery within the last month, or recent vaccinations. Data from this cohort also contributed to our previously published study ( 25 ).…”

A Systematic Review and Meta-Analysis of Alpha Synuclein Auto-Antibodies in Parkinson's Disease

“…Immune dysfunction has been associated with PD and its progression ( 2 – 5 ) and represents a tractable target for disease modification. However, the cellular and molecular mechanisms underpinning this association have yet to be elucidated.…”